Get startedLog in
    Picture of OncoTherapy Science logo

    4564 — OncoTherapy Science Income Statement

    0.000.00%
    jp flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for OncoTherapy Science, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    2026
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:YuhoYuhoYuhoYuhoTanshin
    Standards:
    JAS
    JAS    		—
    JAS    		—
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,1541,135610750809
    Cost of Revenue
    Gross Profit11441.7-178-12.814
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses3,7052,2251,8801,5461,682
    Operating Profit-2,551-1,090-1,270-796-873
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-2,570-1,116-1,286-813-908
    Provision for Income Taxes
    Net Income After Taxes-2,572-1,119-1,288-815-911
    Net Income Before Extraordinary Items
    Net Income-2,572-1,119-1,288-815-911
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-2,572-1,119-1,288-815-911
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-12-5.86-5.6-3.13-2.65
    Dividends per Share